Disclosure Policy Statement

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Nurses Credentialing Center (ANCC) and the Accreditation Council for Pharmacy Education (ACPE), The American Heart Association must ensure fair balance, independence, objectivity, and scientific rigor in all its individually sponsored or jointly sponsored educational activities. Therefore, all individuals (planning committee members, speakers, moderators and authors) who develop and/or control the educational content of continuing education activities sponsored by the American Heart Association must disclose to the audience: (1) any financial relationships with commercial interests whose lines of business are related to the educational content of the activity and/or any financial relationships with the commercial supporters of the activity, and (2) unlabeled/unapproved uses of drugs or devices discussed in their presentation. Such disclosures will be made in writing in the activity materials. (Examples of financial relationships can include grants or research support, commercial interest employee, consultant, major stockholder, speaker’s bureau member, etc. occurring within the last 12 months.) The intent of this disclosure is to identify and resolve any existing conflicts of interest so that the commercial independence of this activity can be assured. In addition, these disclosures provide participants with the requisite information needed to make their own judgments with regard to conflicts of interest.

I. The following individuals have declared financial interest(s) and/or affiliation(s):

<table>
<thead>
<tr>
<th>NAME</th>
<th>ROLE</th>
<th>DISCLOSURES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Brewster</td>
<td>Program Committee</td>
<td>Expert Witness, Grant LLC, Wiseman LLC</td>
</tr>
<tr>
<td>Rosanne Crooke</td>
<td>Invited Speaker</td>
<td>Employment; Ionis Pharmaceuticals. Employment; Modest; Consultant Ionis Pharmaceuticals.</td>
</tr>
<tr>
<td>Naomi Hamburg</td>
<td>Program Committee</td>
<td>Spouse is General Counsel for Acceleron Pharma; Consultant/Advisory Board: Merck</td>
</tr>
<tr>
<td>Peter Henke</td>
<td>Program Committee</td>
<td>Consultant/Advisory Board: Admedus</td>
</tr>
<tr>
<td>Jeffrey Hubbell</td>
<td>Invited Speaker</td>
<td>Ownership Interest: MorphoGene SA; Consultant/Advisory Board: MorphoGene SA</td>
</tr>
<tr>
<td>Maureane Hoffman</td>
<td>Invited Speaker</td>
<td>Research Grant: Novo Nordisk; Shire/Takeda Pharmaceuticals; Consultant: CSL Behring</td>
</tr>
<tr>
<td>Steven Lentz</td>
<td>Program Committee</td>
<td>Consultant/Advisory Board: Novo Nordisk; Opko (Data Safety Monitoring board)</td>
</tr>
<tr>
<td>Dianna Milewicz</td>
<td>Invited Speaker</td>
<td>Research Grant; Modest; AHA, NIH, Genetic Aortic Disease Association of Canada, Marfan Foundation, Department of Defense. Other Research Support; Modest; John Ritter Foundation.</td>
</tr>
<tr>
<td>Kiran Musunuru</td>
<td>Program Committee</td>
<td>Other: Verve Therapeutics, Scientific Advisor</td>
</tr>
<tr>
<td>Pradeep Natarajan</td>
<td>Invited Speaker</td>
<td>Research Grant; Amgen, Boston Scientific, Apple. Other; Apple. Research Grant; Significant; Apple, Boston Scientific. Consultant/Advisory Board; Modest; Apple, Blackstone Life Sciences.</td>
</tr>
<tr>
<td>Manuel Navedo</td>
<td>Program Committee</td>
<td>Other: NIH VCMB Study Section Reviewer</td>
</tr>
<tr>
<td>A. Philip Owens</td>
<td>Program Committee</td>
<td>Research Grant; National Institutes of Health, Bayer Pharmaceuticals, American Heart Association.</td>
</tr>
<tr>
<td>Aruna Pradhan</td>
<td>Program Committee</td>
<td>Research Grant: Kowa Research Institute, Inc., Denka Seiken</td>
</tr>
<tr>
<td>Kerry Anne Rye</td>
<td>Program Committee</td>
<td>Other: Editor-in-Chief Journal of Lipid Research; Consultant: CSL</td>
</tr>
<tr>
<td>NAME</td>
<td>ROLE</td>
<td>DISCLOSURES</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Thomas Wang</td>
<td>Program Committee</td>
<td>Labcorp - (&gt;1 year ago) Assay support: Not Significant * Diasorin - assay support (2015, 2017); (&gt;2 years ago) SAB, consulting fees, research support, honoraria: Not Significant * Ultrageny - Advisory Board meeting, October 2015: Not Significant * Takeda pharmaceuticals - Advisory board, April 2019: Not Significant * Siemens Healthcare Diagnostics - (&gt;1 year ago) Assay support: Not Significant * Pfizer - ad hoc advisory board meeting, October 2013: Not Significant * Novartis - Data science advisory board, February 2019: Significant * Brahms - (&gt;1 year ago) Licensing fees, assay support: Not Significant * Singulex - (&gt;1 year ago): medical Advisory Board, honoraria, assay support: Not Significant * Critical Diagnostics - (&gt;1 year ago) Assay support, reimbursed travel to meeting in March 2014: Not Significant</td>
</tr>
<tr>
<td>Nancy Webb</td>
<td>Program Committee</td>
<td>Research Grant: NIH</td>
</tr>
</tbody>
</table>

II. The following individuals have declared NO financial interest(s) and/or affiliation(s):

Elena Aikawa ................... Invited Speaker
Elisa Boscolo.................... Invited Speaker
Yabing Chen .................... Program Committee
Ronald Dalman.................... Invited Speaker
Scott Damrauer.................. Program Committee
Alan Daugherty................... Program Committee
Jane Freedman.................... Invited Speaker, Program Committee
Chiara Giannarelli ............ Invited Speaker
Delphine Gomez ................ Program Committee
Isabella Grumbach ............. Program Committee
Catherine (Lynn) Hedrick ....... Invited Speaker
Ngan Huang ..................... Program Committee
M. Luisa Iruela-Arispe ....... Invited Speaker
Helle Jorgensen ................ Invited Speaker
Milka Koupenova ................. Invited Speaker
Joseph Loscalzo ................ Invited Speaker
Esther Lutgens.................. Invited Speaker, Program Committee
Nigel Mackman ................... Invited Speaker
Lars Maegdefessel ............. Program Committee
Kathleen Martin ................. Program Committee
Coleen McNamara ............... Program Committee
Clint Miller ..................... Program Committee
Chieko Mineo .................... Invited Speaker
Sanjay Misra .................... Program Committee, Invited Speaker
Marvin Nieman ................... Program Committee
Andrea Obi ....................... Invited Speaker
Hiroaki Okazaki ................ Invited Speaker
Katey Rayner .................... Program Committee
Babak Razani ..................... Program Committee
Muredach Reilly ................. Program Committee
Alan Remaley .................... Program Committee
Gissette Reyes-Soffer ....... Program Committee
Nalini Santanam ................. Program Committee
Oliver Soehnlein ............... Program Committee
Mary Sorci-Thomas ............. Program Committee
Thomas Vallim ................... Program Committee
Miao Wang ....................... Program Committee
Randal Westrick ................. Program Committee
Alisa Wolberg ................... Program Committee
Dennis Wolf ..................... Program Committee
Xia Yang ......................... Invited Speaker

III. The following individuals will discuss unlabeled/unapproved uses of drug(s) or device(s) in their presentations:

None